ObjectivesTo systematically review the association between the expression level of LncRNA and clinicopathological features and prognostic value of gastric cancer.MethodsWe searched PubMed, EMbase, The Cochrane Library, Web of Science, CNKI, VIP, WanFang Data and CBM databases to collect studies on the association between LncRNA overexpression and prognosis for gastric cancer from inception to April 2017. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies, then, meta-analysis was performed by using Stata 12.0 software.ResultsA total of 21 case-control studies were included. The results of meta-analysis showed that: LncRNA overexpression patients had poor TNM stage (OR=0.29, 95%CI 0.24 to 0.35, P<0.001), deeper tumor invasion (OR=0.24, 95%CI 0.12 to 0.49,P<0.001), shorter overall survival (OS) (HR=2.52, 95%CI 2.07 to 3.06,P<0.001) and disease-free survival (DFS) (HR=2.31, 95%CI 1.75 to 3.05,P<0.001).ConclusionsLncRNA overexpression is a poor prognosis risk factor for gastric cancer patients. Due to limited quantity and quality of the included studies, more high quality studies are needed to verify above conclusions.
Objective To explore relationship between long non-coding RNA maternally expressed gene 3 (MEG3) polymorphisms and risk of gastric cancer. Methods One hundred and seventy-two Han patients with gastric cancer (gastric cancer group) and 224 Han individuals for physical examination (control group) in the Yunnan Cancer Hospital from March 2013 to October 2017 were selected as subjects. The rs7158663 and rs4081134 polymorphisms of the MEG3 were genotyped by using a TaqMan technique. The associations between the 2 polymorphisms and the risk of the gastric cancer and its clinical features were analyzed using the SPSS software. Results The frequencies of the AG+AA genotype and the A allele of the MEG3 rs7158663 in the gastric cancer group were significantly higher than those in the control group using the GG genotype and G allele as a reference respectively ［adjusted OR=1.71, 95%CI (1.14, 2.56), P=0.010; adjusted OR=1.58, 95%CI (1.15, 2.19), P=0.005］ after the Chi-square test and the adjustment of age and gender. The frequencies of the AG+AA genotype and the A allele of the MEG3 rs4081134 had no significant differences between the gastric cancer group and the control group (P>0.017). Moreover, the polymorphisms of the MEG3 rs7158663 and rs4081134 were not associated with the clinical features of the gastric cancer (P>0.017). Conclusion MEG3 rs7158663 AG+AA genotype might be one of susceptibility gene of gastric cancer in Chinese Han population.
ObjectiveTo summarize research progress of non-coding RNAs (ncRNAs) in acute pancreatitis (AP), so as to provide new ideas for pathogenesis, diagnosis, and therapy of AP.MethodThe literatures on studies of ncRNAs in AP in recent years were read and reviewed.ResultsThe incidence of AP was currently increasing, but its etiology was diverse, and its pathogenesis was still fully unclear. In recent years, a large number of studies had confirmed that the ncRNA played an important role in the occurrence of many cellulars and diseases processes. Through continuous exploration for potential mechanisms of AP based on ncRNA (including long non-coding RNA and microRNA) function, it was found that the specificity and sensitivity of ncRNAs in the diagnosis of AP were better than of the traditional biomarkers. Meanwhile, ncRNAs were involved in the regulation of inflammatory response through a variety of ways.ConclusionsncRNAs are involved in altering gene expression (including up-regulation or down-regulation) in the key physiological functions of AP through a variety of ways, it might provide new ideas for understanding pathogenesis of AP and help to find new therapeutic targets. A variety of ncRNAs closely related to AP are expected to become biomarkers and molecular targets for early diagnosis and treatment of AP, so as to achieve early diagnosis and targeted treatment of AP.
ObjectiveTo summarize the research progress of long non-coding RNA (lncRNA) in the regulation of malignant biological behavior of gallbladder cancer so as to provide references for its related research.MethodThe relevant literatures about studies of lncRNA in gallbladder cancer in recent years were reviewed.ResultsThe recent studies had shown that 19 lncRNAs associated with gallbladder cancer had played the important roles in regulating tumor cell proliferation, migration, invasion, apoptosis, “sponge” miRNAs, chemoresistance, and tumor metastasis. Among them, most lncRNAs tended to have carcinogenic properties, only a few had anticarcinogenic effect. Although the research suggested the mechanism and role of lncRNA to promote or inhibit the occurrence and development of gallbladder cancer, the current research on its mechanism was still limited. In addition, some lncRNAs were found to be specifically expressed in the serum of patients with gallbladder cancer, so which were expected to become biomarkers for tumor diagnosis and prognosis.ConclusionslncRNAs associated with gallbladder cancer have carcinogenic or anticarcinogenic effect, or chemoresistance. They play potential roles in diagnosis, prognosis, and (or) treatment of tumors, but molecular mechanisms of their effects are still limited.
ObjectiveTo understand advances in diagnostic value of long non-coding RNA (LncRNA) in hepatocellular carcinoma (HCC) and to find a useful tumor marker for early diagnosis of HCC.MethodThe recent literatures relevant the LncRNA in the HCC were reviewed and summarized.ResultsThe LncRNA could be detected in the blood and urine of the patients by the RNA immunoprecipitation, sequencing technology, gene chip, real-time quantitative PCR, and other techniques. With the rise of RNA sequencing technology, the number of identified LncRNAs had increased rapidly, and the remarkable progress had been made in the field of liver diseases. At present, the LncRNA related to HCC mainly included the urothelial cancer associated 1, highly up-regulated in liver cancer, metastasis-associated lung adenocarcinoma transcript 1, HOXA transcript at the distal tip, H19, SPRY4 intronic transcript 1, plasma-cytoma variant translocation gene 1, uc002mbe.2, uc007biz.1, etc., which were stable in the blood or urine and abnormally expressed in the HCC, alone or as a supplement to alpha-fetoprotein could obviously improve the sensitivity and specificity of diagnosis of HCC, even increased the sensitivity to 100%.ConclusionsLncRNA is specifically expressed in HCC and is expected to be a novel biomarker for early diagnosis of HCC. However, LncRNA has many types, diverse structures, and complex molecular regulation mechanisms. It is very difficult to find a strong combination or combinations to replace or supplement traditional biomarkers and to be clinically useful further efforts. It is believed that with deepening of LncRNA research in HCC, it will have a broader prospect in early screening, diagnosis, and prognosis of HCC.
ObjectiveTo study value of long noncoding RNA H19 and HOTTIP in plasma in predicting efficacy of neoadjuvant chemotherapy (NAC) for resectable locally advanced gastric cancer. MethodsForty patients with T3–4aN+M0 gastric cancer and 40 patients with benign gastric diseases treated in the Yantai Yuhuangding Hospital Affiliated to Qingdao University from August 2020 to May 2021 were prospectively included. The expressions of H19 and HOTTIP in the plasma of gastric cancer and benign gastric diseases patients without any treatment after admission were detected before treatment (CAPEOX regimen was used in the patients with gastric cancer), then which were detected after 2 NAC courses for patients with gastric cancer. Meanwhile, some clinical items were detected and the efficacy of NAC was evaluated. The complete remission (CR) and partial remission (PR) were classified as objective remission, CR, PR, and disease stability were classified as disease control. The expressions of H19 and HOTTIP between the different patients were compared and the receiver operating characteristic (ROC) curve was used to evaluate their values in the diagnosis of resectable locally advanced gastric cancer. ResultsThere were 13 cases of T downstaging and 27 cases of T non-downstaging and 25 cases of objective remission and 35 disease control after NAC. The median relative expression levels of H19 and HOTTIP before NAC in the patients with gastric cancer were higher than those in the patients with benign gastric diseases (H19: 1.42 versus 0.98, Z=–3.835, P<0.001; HOTTIP: 2.15 versus 1.04, Z=–5.062, P<0.001), and which were in the patients with T downstaging and disease control were lower than those in the patients with T non-downstaging and 5 cases of disease progression (For T staging, H19: 1.12 versus 1.54, Z=–2.960, P=0.002; HOTTIP: 1.49 versus 2.30, Z=–2.310, P=0.019. For efficacy of NAC, H19: 1.39 versus 2.48, Z=–3.211, P<0.001; HOTTIP: 1.96 versus 3.25, Z=–2.393, P=0.014). The median relative expressions of H19 and HOTTIP after NAC were lower than those before NAC in the patients with gastric cancer (H19: 1.12 versus 1.42, Z=–3.965, P<0.001; HOTTIP: 1.30 versus 2.15, Z=–4.839, P<0.001). There were no significant differences in the changes of H19 and HOTTIP before and after NAC between the patients with T downstaging and T non-downstaging, and between disease control and disease progression (P>0.05). The areas of ROC curve of H19, HOTTIP, and combination of H19 and HOTTIP in diagnosis of resectable locally advanced gastric cancer were higher than 0.7. ConclusionsLncRNA H19 and HOTTIP might be potential tumor markers in gastric cancer, and their diagnostic values for resectable locally advanced gastric cancer are higher. Gastric cancer patients with low expressions of H19 and HOTTIP in plasma might be more sensitive to NAC.
ObjectiveTo evaluate the expression level and diagnostic value of lnc-PAPSS2-2 (lnc-PA) in peripheral blood of active pulmonary tuberculosis (PTB) patients.MethodsFrom January 2011 to January 2018, 798 patients with active PTB and 1 650 healthy people undergoing health examination in West China Hospital of Sichuan University and their electronic health records (EHR) were collected. Peripheral blood lnc-PA levels were quantified by quantitative real-time polymerase chain reaction method. The data of lnc-PA and EHR were modeled using nomogram, and the receiver operating characteristic (ROC) curves of lnc-PA, EHR and the combination of lnc-PA and EHR were compared to evaluate the diagnostic value of lnc-PA for active PTB.ResultsThe level of lnc-PA was lower in active PTB patients than that in healthy controls (P<0.001). The areas under ROC curve of lnc-PA, EHR and their combination were 0.619, 0.962, and 0.964 in the training set and 0.626, 0.950, and 0.950 in the validation set, respectively.ConclusionThe diagnostic ability of lnc-PA is poor and that of EHR is good, which indicates that the clinical value of lnc-PA as a biomarker of active PTB remains to be further explored.
ObjectiveTo investigate the level of serum long non-coding RNA antisense non-coding RNA INK4 locus (LncRNA ANRIL) in patients with ulcerative colitis (UC), and to analyze the diagnostic value of serum LncRNA ANRIL level in UC. MethodsA total of 143 UC patients admitted to the First Affiliated Hospital of Henan University of Science and Technology from February 2015 to November 2019 were retrospectively analyzed, and 145 healthy people with normal physical examination in the First Affiliated Hospital of Henan University of Science and Technology were selected as the control group. The relationship between serum LncRNA ANRIL level and PCT/IL-17 level was analyzed, the serum levels of LncRNA ANRIL, PCT, and IL-17 were compared between the two groups, and their diagnostic value for UC was explored.ResultsThe disease degree of 143 UC patients: 41 cases were mild, 59 cases were moderate, and 43 cases were severe; endoscopic grade: 38 cases were grade Ⅰ, 65 cases were grade Ⅱ, and 40 cases were grade Ⅲ. Compared with the control group, the serum levels of LncRNA ANRIL, PCT, and IL-17 were increased in the UC group (P<0.05); the levels of serum LncRNA ANRIL, PCT, and IL-17 in the UC group increased gradually with the increase of disease severity and endoscopic grade (P<0.05). The serum levels of LncRNA ANRIL were positively correlated with the levels of PCT and IL-17 in the UC patients (r=0.596, P<0.001; r=0.492, P<0.001). The area under the curve (AUC) of serum LncRNA ANRIL level in the diagnosis of UC was 0.851, the cut-off value was 1.29, the sensitivity and specificity were 75.5% and 83.4%, respectively. The AUC of serum LncRNA ANRIL combined with PCT in the diagnosis of UC was 0.898, the corresponding sensitivity and specificity were 81.8% and 87.6%, respectively. The sensitivity and diagnostic value of combination of LncRNA ANRIL and PCT were higher than that of serum LncRNA ANRIL alone (Z=2.102, P=0.036). ConclusionsThe serum level of LncRNA ANRIL in UC patients is increased, which has a certain diagnostic value, and it combines with PCT can better predict UC.
ObjectiveTo investigate expression and clinical significance of long chain noncoding RNA POU6F2-AS2 in human gastric cancer tissues.MethodsSeventy-three pairs of human gastric cancer and matched paracancerous tissues from May 2017 to May 2018 in the Affiliated Hospital of North Sichuan Medical College were collected. The real-time fluorescence quantitative polymerase chain reaction was used to detect the expression level of POU6F2-AS2 in the gastric cancer tissue and its paracancerous tissue. The correlations between its expression level and clinicalpathologic features of patients were analyzed by the chi-square text. The relationship between the expression of POU6F2-AS2 and the overall survival rate of patient with gastric cancer was analyzed by the Kaplan Meier Plotter database data.ResultsThe relative expression of POU6F2-AS2 in the gastric cancer tissues was significantly higher than that in the corresponding adjacent tissues (P<0.050). The patients were divided into the high expression (43 cases) and low expression group (30 cases) according to the expression level of POU6F2-AS2 in the gastric cancer tissues and their corresponding adjacent tissues. The results of the relationship between the expression of POU6F2-AS2 and the clinicopathologic characteristics of patients with gastric cancer showed that the POU6F2-AS2 expression was significantly correlated with the depth of invasion (P=0.022) or the TNM stage (P=0.032). There were no significant differences in the gender, age, smoking history, drinking history, tumor diameter, degree of differentiation, lymph node metastasis, distant metastasis, vascular invasion, nerve invasion, liver metastasis, ascites, and fat nodule metastasis (P>0.050). The overall survival rate of high expression of POU6F2-AS2 in the patient with gastric cancer was significantly worse than that of the low expression of POU6F2-AS2 by the Kaplan Meier Plotter database.ConclusionsHigh expression of POU6F2-AS2 is related to depth of tumor invasion and TNM stage, which indicates that POU6F2-AS2 might play an important role in regulating occurrence and development of gastric cancer. It may be used as an important target for gene diagnosis and treatment of gastric cancer and as a biomarker for evaluating prognosis of patients with gastric cancer.
ObjectiveCombined with long non-coding RNA (lncRNA) to find a regression model that can be used to predict the survival rate of patients with colon cancer before operation.MethodsThe clinical information and gene expression information of patients with colon cancer were downloaded by using TCGA database. The differentially expressed lncRNAs in tumor and paracancerous tissues were screened out, and then combined with the clinical information of patients to construct Cox proportional hazard regression model.ResultsA total of 26 kinds of lncRNAs with statistical difference in gene expression between paracancerous tissues and tumor tissues were selected (P<0.05). Through repeated screening and comparison of prediction efficiency, the prediction model was finally selected, which was constructed by patients’ age, M stage, N stage, and three kinds of lncRNAs (ZFAS1, SNHG25, and SNHG7) gene expression level: age [HR=4.00, 95%CI: (1.48, 10.84), P=0.006], M stage [HR=3.96, 95%CI: (2.23, 7.04), P<0.001], N stage [HR=1.87, 95%CI: (1.24, 2.84), P=0.003], ZFAS1 gene expression level [HR=0.60, 95%CI: (0.41, 0.86), P=0.006], SNHG25 gene expression level [HR=0.85, 95%CI: (0.73, 1.00), P=0.045], and SNHG7 gene expression level [HR=2.32, 95%CI: (1.53, 3.52), P<0.001] were all independent risk factors for postoperative survival of patients with colon cancer. The area under the ROC curves for predicting 1, 3, and 5-year overall survival were 0.802, 0.828, and 0.771, respectiely, which had a good prediction ability.ConclusionThe predictive model constructed by the combination of ZFAS1, SNHG25, SNHG7 genes expression level with M stage, N stage, and age can better predict the overall survival rate of patients before operation, which can effectively guide clinical decision-making and choose the most suitable treatment method for patients.